Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer seeks to correct defect in Lipitor patent

Executive Summary

Pfizer files a reissue application with the U.S. Patent Trademark Office to correct a "technical defect" in its patent covering the active enantiomeric form of its blockbuster Lipitor, Pfizer's 2006 financial report indicates. A panel of the U.S. Court of Appeals for the Federal Circuit ruled in August 2006 that a patent claim was invalid on technical grounds. The court also affirms that the basic patent covering Lipitor is valid and thus infringed by Ranbaxy's ANDA for atorvastatin. Ranbaxy, according to Pfizer, filed a petition for a writ of certiorari in January to the Supreme Court to have the Federal Circuit panel's ruling reviewed...

You may also be interested in...

Woodcock Faces Maze Of Rules To Become Commissioner Nominee

Vacancies Reform Act requires individual in an acting position to step down in order to be nominated to the permanent post but there are exceptions. Andrew von Eschenbach retained acting title during his nomination in 2006.

Even As Acting US FDA Commissioner, Woodcock Still Holds Multiple Positions

To help with the transition to Biden’s COVID-19 response, Woodcock will retain some therapeutic development duties in the program the Trump administration had called Operation Warp Speed.

Medicare Part D Protected Classes Targeted in Last-Minute Payment Demo Update

If not reversed by the Biden Administration, demo program that puts plans at increased risk in catastrophic phase would also enhance negotiating leverage for drugs in the protected classes.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts